ReviewFrontiers in oncology2020
The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- A comprehensive bibliometric analysis of ferroptosis in tumor resistance: development and emerging trends.Frontiers in immunology · 2025Pooled it
- Development of m6A-related prognostic models for survival in lung squamous cell carcinoma with different PD-L1 expression levels.Translational cancer research · 2026Article
- The m6A Reader IGF2BP2 Suppresses Ferroptosis in Nasopharyngeal Carcinoma by Stabilizing NRF2 mRNA.Biochemical genetics · 2026Article
- Epigenetic plasticity in cancer drug resistance: mechanistic insights and strategies for therapeutic intervention.Acta pharmacologica Sinica · 2026Review
- The relevance of mJournal of cancer research and clinical oncology · 2026Review
- Methyltransferase-Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A.Cancer reports (Hoboken, N.J.) · 2026Article
- Radiotherapy combined with anti-PD-1 immunotherapy promotes ferroptosis-driven control of hepatocellular carcinoma.Genes and immunity · 2026Article
- Potential regulatory role of the mActa biochimica et biophysica Sinica · 2025Review
- Knockdown of IGF2BP2 overcomes cisplatin-resistance in lung cancer through downregulating Spon2 gene.Hereditas · 2024Article
- Role of N6-methyladenosine RNA modification in cancer.MedComm · 2024Review
- YTHDC1 mThe EMBO journal · 2024Article
- WTAP promotes proliferation of esophageal squamous cell carcinoma via mCancer science · 2024Article
- The identification of a NAging · 2024Article
- FAM120A deficiency improves resistance to cisplatin in gastric cancer by promoting ferroptosis.Communications biology · 2024Article
- METTL3-mediated mEpigenetics · 2023Article
- FTO Sensitizes Oral Squamous Cell Carcinoma to Ferroptosis via Suppressing ACSL3 and GPX4.International journal of molecular sciences · 2023Article
- Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC).Heliyon · 2023Review
- The crucial roles of mGenes & diseases · 2023Review
- Interaction between NMolecular medicine (Cambridge, Mass.) · 2023Review
- CircRNAs: A Promising Star for Treatment and Prognosis in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
m6A RNA methylation, which serves as a critical regulator of transcript expression, has gathered tremendous scientific interest in recent years. From RNA processing to nuclear export, RNA translation to decay, m6A modification has been studied to affect various aspects of RNA metabolism, and it is now considered as one of the most abundant epitranscriptomic modification. RNA methyltransferases (writer), m6A-binding proteins (readers), and demethylases (erasers) proteins are frequently upregulated in several neoplasms, thereby regulating oncoprotein expression, augmenting tumor initiation, enhancing cancer cell proliferation, progression, and metastasis. Though the potential role of m6A methylation in growth and proliferation of cancer cells has been well documented, its potential role in development of therapy resistance in cancer is not clear. In this review, we focus on m6A-associated regulation, mechanisms, and functions in acquired chemoresistance, radioresistance, and resistance to immunotherapy in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.